The US Bankruptcy Court gave an order approving the sale of substantially all the assets of Acorda Therapeutics, Inc. on June 12, 2024. The debtor has been authorized to sell substantially all its assets to Merz Pharmaceuticals, LLC for a purchase price of $185 million in cash plus the amount, if any, of the Net Working Capital Adjustment.